Proximo to Commercialize Biotronik's PVI Portfolio in Select United States Markets

September 16, 2019—Proximo Medical, LLC announced that it is the commercial partner for Biotronik, Inc.'s peripheral vascular intervention (PVI) platform in select United States markets.

Proximo Medical is a fractional commercial organization for start-up medical device technologies and established medical device companies seeking to expand adoption on select products in the United State market. The company provides market validation, an experienced workforce, and scalability to deliver patients and physicians the best care in a cost-effective model.

Biotronik, which is headquartered in Berlin, Germany, has United States offices in New York, New York and Lake Oswego, Oregon. The company's PVI portfolio is designed for the treatment of peripheral artery disease and includes the 4-F Pulsar self-expanding stent, which is approved in the United States. Additional products include the Astron stent system, Passeo percutaneous transluminal angioplasty balloon catheters, and Fortress introducer sheaths.

Craig Walker, MD, who is President and Medical Director of Cardiovascular Institute of the South, Clinical Professor of Medicine at Tulane Medical School, and Clinical Professor of Medicine at LSU Medical School in New Orleans, Louisiana, commented in the company's announcement, "I was an investigator in the trial of the Biotronik Pulsar stent. I was impressed that this stent, which has a 4-F delivery system, was easy to deploy accurately and had good clinical patency. I think this will be very helpful particularly in cases where standard 5-F or 6-F sheaths may be occlusive."